| HOME >> BIOLOGY >> TECHNOLOGY |
Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements
that involve a number of risks and uncertainties. Such forward-looking
statements include statements about Arena's strategy, internal and
partnered programs, and ability to develop compounds and commercialize
drugs. For such statements, Arena claims the protection of the Private
Securities Litigation Reform Act of 1995. Actual events or results may
differ materially from Arena's expectations. Factors that could cause
actual results to differ materially from the forward-looking statements
include, but are not limited to, clinical trials and studies may not
proceed at the time or in the manner Arena expects or at all, the results
of clinical trials or preclinical studies may not be predictive of future
results, Arena's ability to partner lorcaserin, APD125, APD791 or other of
its compounds or programs, the timing, success and cost of Arena's
research, out-licensing endeavors and clinical trials, Arena's ability to
obtain additional financing, Arena's ability to obtain and defend its
patents, the timing and receipt of payments and fees, if any, from Arena's
collaborators, and Arena's ability to redeem with common stock any
outstanding shares of its series B convertible preferred stock. Additional
factors that could cause actual results to differ materially from those
stated or implied by Arena's forward-looking statements are disclosed in
Arena's filings with the Securities and Exchange Commission. These forward-
looking statements represent Arena's judgment as of the time of this
release. Arena disclaims any intent or obligation to update these
forward-looking statements, other than as may be required under applicable
la
'/>"/>
| SOURCE Arena Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |